Brittany A. Borden

Also affiliated with Cancer Genetics (United States)

Biochemistry, Genetics and Molecular BiologyMedicineChemistryPharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics”.

Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics

npj Genomic Medicine(2021)10.1038/s41525-021-00253-1

N/A

0.406DataRank · unranked

14 citations

Keith Danahey, Brittany A. Borden, Elizabeth Lipschultz, Maimouna Traore, Mark J. Ratain +3 more

Pharmacogenomic‐Based Decision Support to Predict Adherence to Medications

Clinical Pharmacology & Therapeutics(2020)10.1002/cpt.1838

N/A

0DataRank · unranked

22 citations

Brittany A. Borden, Keith Danahey, Kiang-Teck J Yeo, Xander M.R. van Wijk, Mark J. Ratain +2 more

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer

International Journal of Molecular Sciences(2023)10.3390/ijms241310870

N/A

0DataRank · unranked

25 citations

Anna D. Louie, Praveen R. Srinivasan, Christoph Schorl, Shaolei Lu, David Silverberg +9 more

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.07.527499

N/A

0DataRank · unranked

6 citations

Anna D. Louie, Praveen R. Srinivasan, Christoph Schorl, Shaolei Lu, David Silverberg +9 more

GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15138

N/A

0DataRank · unranked

1 citations

Kelsey E. Huntington, Anna D. Louie, Praveen Srinivasan, Cristoph Schorl, Shaolei Lu +10 more